Head and Neck Cancer Clinical Trial
Official title:
A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia
RATIONALE: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) and
pilocarpine may help to relieve chronic xerostomia (dry mouth). It is not yet known which
remedy is more effective in treating chronic dry mouth caused by radiation therapy in
patients with head and neck cancer.
PURPOSE: This randomized phase II/III trial is studying ALTENS to see how well it works
compared with pilocarpine in treating chronic dry mouth caused by radiation therapy in
patients with head and neck cancer.
OBJECTIVES:
Primary
- Determine the feasibility of successfully delivering acupuncture-like transcutaneous
electrical nerve stimulation (ALTENS) using the Codetron™ unit in a cooperative group
setting in head and neck cancer patients with early radiotherapy-induced xerostomia.
(phase II)
- Compare the efficacy of ALTENS treatment vs pilocarpine hydrochloride in these patients
in reducing overall xerostomia burden, as measured by the University of Michigan 15-item
Xerostomia-Related Quality of Life Scale (XeQOLS) at 9 months after randomization.
(phase III)
Secondary
- Evaluate the effect of ALTENS treatment on overall xerostomia burden at 6 months after
study entry in these patients. (phase II)
- Compare the efficacy of these treatments in these patients in reducing overall
xerostomia burden at 4, 6, and 15 months after randomization. (phase III)
- Compare the efficacy of these treatments in these patients in reducing symptom burden,
as measured by the four domains of the XeQOLS (i.e., physical functioning, social
functioning, personal/psychological functioning, and pain/discomfort) at 4, 6, 9, and 15
months after randomization. (phase III)
- Compare the efficacy of these treatments in these patients in increasing stimulated
(i.e., citric acid primed) whole salivary production (WSP), as measured by sialometry,
at 4, 6, 9, and 15 months after randomization. (phase III)
- Compare the efficacy of these treatments in these patients in increasing unstimulated
(i.e., basal primed) WSP, as measured by sialometry at 4, 6, 9, and 15 months after
randomization. (phase III)
- Compare adverse events associated with these treatments in these patients. (phase III)
OUTLINE: This is a phase II followed by a phase III multicenter study.
- Phase II:Patients undergo placement of surface electrodes at the following acupuncture
points: large intestine, spleen, stomach, and conception vessel. Patients then undergo
acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) to each of these
points using the Codetron™ unit for 20 minutes twice weekly for 12 weeks. No further
treatment is given after 12 weeks.
- Phase III:Patients are stratified according to prior use of pilocarpine (no vs yes) and
length of time from completion of chemotherapy and/or radiotherapy (3-6 months vs 6-12
months vs > 12 months). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral pilocarpine three times daily for up to 12 weeks in
the absence of disease progression or unacceptable toxicity.
- Arm II: Patients undergo ALTENS treatment using the Codetron™ unit twice weekly for
up to 12 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo quality of life (QOL) assessment at baseline and at 6 months after
registration in phase II. In phase III patients complete assessments for basal and stimulated
whole salivary production, xerostomia burden, and QOL at baseline and at 4, 6, 9, and 15
months after study entry.
After completion of study therapy, patients are followed at 3 months.
PROJECTED ACCRUAL: A total of 45 patients will be accrued to the phase II portion and 144
patients to the phase III portion of this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |